
51 - 200 employees
Founded 2014
🧬 Biotechnology
đź’Š Pharmaceuticals
🏥 Healthcare
Biotechnology • Pharmaceuticals • Healthcare
SAB BIO is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency human immunoglobulin G (hIgG) therapies to treat and prevent immune and autoimmune disorders, with a stated mission to redefine diagnosis and treatment of type 1 diabetes (T1D) through disease-modifying medicines. Founded in 2014 and traded on Nasdaq (SABS) since 2021, SAB BIO uses proprietary genetic engineering and antibody technologies to generate therapeutic candidates without relying on human donors or convalescent plasma. The company has conducted seven clinical trials dosing roughly 700 individuals across multiple therapeutic areas, reporting no patients with serum sickness or neutralizing anti-drug antibodies in its safety and immunogenicity database. Its lead candidate, SAB-142, is aimed at delaying onset and potentially preventing progression of Stage 3 T1D.
đź•’ July 27
Improve your chances of getting an interview by checking your resume score before you apply.

51 - 200 employees
Founded 2014
🧬 Biotechnology
đź’Š Pharmaceuticals
🏥 Healthcare
Biotechnology • Pharmaceuticals • Healthcare
SAB BIO is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency human immunoglobulin G (hIgG) therapies to treat and prevent immune and autoimmune disorders, with a stated mission to redefine diagnosis and treatment of type 1 diabetes (T1D) through disease-modifying medicines. Founded in 2014 and traded on Nasdaq (SABS) since 2021, SAB BIO uses proprietary genetic engineering and antibody technologies to generate therapeutic candidates without relying on human donors or convalescent plasma. The company has conducted seven clinical trials dosing roughly 700 individuals across multiple therapeutic areas, reporting no patients with serum sickness or neutralizing anti-drug antibodies in its safety and immunogenicity database. Its lead candidate, SAB-142, is aimed at delaying onset and potentially preventing progression of Stage 3 T1D.
• Provide strategic, operational, and technical leadership for the company’s manufacturing activities. • Establish scalable, compliant, and cost-effective manufacturing capabilities. • Lead manufacturing network strategy, CDMO management, technology transfer, scale-up, process validation, operational readiness, and reliable commercial supply. • Ensure that manufacturing operations meet global regulatory expectations and maintain a strong culture of safety, quality, compliance, and continuous improvement. • Develop and execute the overall manufacturing strategy supporting late-stage clinical development and commercial launch readiness. • Provide executive leadership and oversight of CDMO partners supporting bulk process intermediates and drug product manufacturing activities. • Oversee technology transfer of manufacturing processes to external partners and support scale-up from development through commercial production. • Ensure successful execution of cGMP manufacturing campaigns supporting clinical supply and future commercial supply.
• Ph.D. in Chemical Engineering, Biochemistry, Pharmaceutical Sciences, or a related discipline preferred. • Advanced scientific degree strongly preferred. • 15+ years of progressive experience in biologics manufacturing, technical operations, CMC, or pharmaceutical operations. • Significant experience leading GMP manufacturing operations and managing outsourced biologics manufacturing through CDMOs. • Demonstrated success supporting late-stage clinical programs. • Experience leading technology transfer, process validation, scale-up, and commercial readiness for immunoglobulin-based or protein-based products. • Expertise in plasma fractionation, plasma-derived therapeutics, high-purity protein purification, or analogous large-scale separation and purification processes is desired. • Proven track record contributing to global regulatory filings and CMC documentation. • Experience supporting BLA submissions, pre-approval inspections, regulatory inspections, and commercial launch readiness activities strongly preferred. • Strong experience building and leading high-performing technical teams.
• Health insurance • Retirement plans • Paid time off • Flexible work arrangements • Professional development
Apply Nowđź•’ July 27
Vice President of Sales leading national commercial organization for Xenter Diagnostics. Driving adoption of diagnostic solutions and building a high-performing sales team.
đź•’ July 27
Vice President, External Relations for TEACH driving business development and relationship management with state partners. Seeking strategic fundraiser to build new relationships and ensure revenue goals are met.
đź•’ July 27
Vice President, Clinical Development leading oncology initiatives at Allogene Therapeutics, a biotech firm specializing in CAR T products. Working cross-functionally to drive clinical trial strategy and execution.
đź•’ July 25
Regional sales vice president leading strategic SaaS identity-security accounts for SailPoint, a provider of enterprise identity-security solutions. Managing sales teams, partners, forecasting, pipeline, and regional growth plans across TOLA.
🇺🇸 United States – Remote
đź’µ $126k - $212.5k / year
⏰ Full Time
đź”´ Lead
đź‘” Vice President
🦅 H1B Visa Sponsor
đź•’ July 25
Vice President, Strategic Partnerships & Development at CCSA leading philanthropic strategies and donor relationships. Focused on building partnerships and executing effective fundraising operations.
🇺🇸 United States – Remote
đź’µ $129.6k - $150.6k / year
⏰ Full Time
đź”´ Lead
đź‘” Vice President